期刊文献+

利用CHO(dhfr^-)细胞高效表达GM-CSFFc_(γ2)^-融合蛋白 被引量:1

HIGH-LEVEL EXPRESSION OF hGM-CSF/Fc_ν2-FUSION PROTEIN IN CHO(dhfr^-) CELLS
下载PDF
导出
摘要 目的 利用二氢叶酸还原酶缺陷型细胞CHO(dhfr - )高效表达融合蛋白GM -CSF Fcγ2-。方法 利用脂质体基因转染技术 ,把含有融合基因GM -CSF Fcγ2-的真核表达质粒pRc CMV2 GM -CSF Fcγ2-和含有二氢叶酸还原酶基因的真核表达质粒pSV2 -dhfr共转染二氢叶酸还原酶缺陷型细胞CHO(dhfr - )中。用G4 18和撤除H、T(次黄嘌呤、胸腺嘧啶核苷 )双筛选 ,获得dhfr +neo +双表型阳性的细胞克隆。取表达产量最高的克隆进行亚克隆 ,并行MTX加压筛选 ,以提高表达量。用RT -PCR、ELISA和Westernblot对表达产物进行鉴定并行MTT法检测表达蛋白的生物学活性。结果 成功地表达出了具有GM -CSF生物学活性的融合蛋白GM -CSF Fcγ2-。结论 该方法可行 ,表达量达到 15μg ml。 Objective To adequately express fusion protein GM-CSF/Fc ν2-using CHO(dhfr -) cells Methods The plasmids pSV2-dhfr and pRc/CMV2/GM-CSF/Fc ν2- were cotransfected into dhfr deficient CHO cells by Lipofection and neo+ dhfr+ positive clones were selected in media containing 600μg/ml G418 and removing Hypoxathine,Thymidine The highest-level expression clone was selected by ELISA,and subcloned in a media containing 10 -7 M MTX The expression of fusion protein GM-CSF/Fc ν2 - was confirmed by RT-PCR,ELISA,Western blot And the biological function of the fusion protein was tested in GM-CSF dependent cells TF-1 Results 1 The highest product was achieved 15μg/10 6cells/24hours 2 The fusion protein possessed the bilolgical function of hGM-CSF Conclusion The method is feasible,the yield of expression attains 15μg/ml
出处 《济宁医学院学报》 2001年第1期27-29,共3页 Journal of Jining Medical University
关键词 融合蛋白 基因表达 细胞CHO GM-CSF/Feγ2^- Fusion protein CHO-dhfr -cell Tansfection Gene expression
  • 相关文献

参考文献9

  • 1Morsyn G, Lieschke GJ, Sheridan W,et al. Clinical experience with recombinant human granulocyte colony- stimulating factorand granulocyte macrophage colony - stimulating factor. semin hematol, 1989,26(suppl 2):9
  • 2Leong, S.P. et al. Recombinant human granulocyte - macrophage colony - stimulatingfactor (rhGM- CSF)and autologous melanoma vaccine mediate tumor regression in patientswith metastatic melanoma. J. Immunother. 1999,22(2): 166
  • 3Samanci, A. et al. Pharmacological administration of granulocyte - macrophagecolony- stimulating factor is of singnificant importance for the induction of a stronghumoral and cellular response in patients immunized with recombinant carcinoembryonicantigen. Cancer Immunol Immunother. 1998,47(3): 131
  • 4Nagai,E.et al. Irradiated tumor cells adenovirally engineered to secretegranulocyte- macrophage colony - stimulating factor establish antitumor immunity andeliminate pre - existing tumors in syngeneic mice. Cancer Immunol Immunother. 1998,47:72
  • 5Chamow SM, Ashkenazi A.Immunoadhesins: principles and applications. TrendsBiotechnol, 1996,14:52
  • 6沈倍奋.靶向CD分子的治疗制剂[J].中国肿瘤生物治疗杂志,1998,5(3):157-159. 被引量:4
  • 7Xin Xiao Zhang, et al. Administration of Noncytolytic IL - 10/Fc in Murine Modelsof Lipopolysaccharide - Induced Septic Shock and Allogeneic Islet Transplantation. TheJournal of Immunology, 1995,154:5590
  • 8朱琛,倪勇,修梅,徐人尔,赵寿元,李昌本.人肿瘤坏死因子可溶性受体Ⅰ与人IgG∶Fc的融合基因的构建及其在大肠杆菌中的表达[J].生物工程学报,1998,14(4):424-428. 被引量:2
  • 9Gorczynski - RM, Cattral - MS, et al. An immunoadhesin incorporating the moleculeOX - 2 is a potent immunosupperssant that prolong allo - and xenograft survival. J -Immunol, 1999,163(3): 1654

二级参考文献2

共引文献4

同被引文献8

  • 1Cuzzole M,Mercurial F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood, 1997,84: 4248~4267
  • 2Sambook J F, Fristsch E F, Maniatis T. Molecular Cloning: A Laboratoty Manual. 2nd. New York: Cold Spring Harbor Laboratotry Press, 1989.16 ~ 572
  • 3Egne J C, Browne J K. Development and characterization of novel erythropoietin stimulating protein ( NESP). Br J Cancer, 2001,84(supple 1) :s3 ~ s10
  • 4Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (EPO) in view of the pharmacokinetics of the recombinant drugs rhEPO and NESP. Eur J Haematol, 2002,69:265 ~ 274
  • 5Darbepoetin alfa :new preparation .Just a me -too :no advantage in anaemia of chronic renal failure. Prescrire Int, 2003, 12 (63): 14~ 16
  • 6Sytkowski A J, Lunn E D, Davis K L, et al. Human erythropoietin dimmers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA,1998,95:1184 ~ 1188
  • 7Sytkowski A J, Lunn E D, Risinger M A, et al. An erythropoietin fusion protein comprised of identical properties. J Biol Chem, 1999,274:24773 ~ 24778
  • 8Dalle B, Henri A, Rouyer Frssard P, et al. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood, 2001,97 (12): 3776 ~ 3782

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部